Compare Sana Biotechnology Inc (SANA) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vertiv Holdings Co — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $812.76M), while Vertiv Holdings Co trades at $248.9 (market cap $94.90B). The key difference: Vertiv Holdings Co is far larger — about 116.8× Sana Biotechnology Inc's market cap, and Vertiv Holdings Co pays a 0.1% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Vertiv Holdings Co for 39 Days on average.
| SANA | VRT | |
|---|---|---|
Market Cap | $812.76M | $94.90B |
Volume | 4,314,200 | 5,469,277 |
Sector | Health | Industrials |
52-Week High | $5.92 | $376.23 |
52-Week Low | $2.68 | $149.83 |
Typical Hold Time | 23 Days | 39 Days |
Enterprise Value | $726.01M | $95.12B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.72, down 1.09% today, showing bearish technical signals with negative moving averages but oversold RSI readings. The company reported no revenue in 2025 with substantial losses (-$244.17M net income) and negative cash flow (-$55.33M), though analyst sentiment remains positive with 82% buy ratings. Recent investor conference presentations highlight ongoing clinical development activities.
While analyst consensus is bullish with a $9.50 price target (Defense World, July 30, 2026), SANA faces significant fundamental challenges including negative profitability metrics and cash burn. Investment appeal hinges on clinical pipeline success, with risks including execution challenges and the pre-revenue biotech business model requiring continued financing.
Vertiv (VRT) trades at $246.49, down 2.63% amid bearish technical signals but maintains strong fundamental momentum with consistent earnings beats and robust AI-driven data center demand. The stock shows elevated valuation multiples (P/E 55.77, P/S 8.42) against impressive profitability (ROE 43.94%, net margin 15.09%), while analyst consensus remains overwhelmingly bullish with a $364.94 price target. Recent news highlights Vertiv's strategic positioning in AI infrastructure cooling solutions.
Outlook remains positive given Vertiv's exposure to the $7.6 trillion AI spending boom (Goldman Sachs, Sep 2026), though risks include potential securities law investigations and competitive pressures. The stock offers growth exposure to data center electrification trends, with Q3 2026 earnings (expected EPS $1.82) serving as the next key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
